The UDP-glucuronosyltransferase (UGT) 2B subfamily of enzymes plays an important role in the metabolism of numerous endogenous and exogenous compounds, including various carcinogens present in tobacco smoke. The goal of the present study was to examine the levels of expression of individual UGT2B genes in various tissues that are targets for tobacco carcinogenesis. Using MT-ATP6 as the experimentally validated housekeeping gene, the highest extrahepatic expression of UGT2B genes was observed in human tonsil, with UGT2B expression levels similar to that observed in human liver. UGT2B17 exhibited high relative expression in most tissues examined, including lung, most tissues of the aerodigestive tract, and pancreas. UGT2B7 expression was highest in pancreas but low or undetectable in most other tissues examined. UGT2B10 expression was high in both tonsil and tongue.
Introduction
The UDP-glucuronosyltransferase (UGT) family of phase II metabolic enzymes play a central role in the excretion of numerous endogenous compounds, including bilirubin (Bosma et al., 1994) and steroid hormones (Belanger et al., 1998 (Belanger et al., , 2003 , as well as exogenous compounds, including various drugs (Nagar and Remmel, 2006) and chemotherapeutic agents (Kemp et al., 2002; Sun et al., 2006 Sun et al., , 2007 Sun et al., , 2010 Balliet et al., 2009 ). The UGTs also play an important role in the metabolism and detoxification of multiple tobacco carcinogens, including tobacco-specific nitrosamines like 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) and its major metabolite 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) (Ren et al., 2000; Wiener et al., 2004a; Chen et al., 2008b) , and polycyclic aromatic hydrocarbons like benzo(a)pyrene [B(a)P]-7,8-diol and dibenzo(a,l)pyrene-11,12-diol [DB(a,l)P] (Fang et al., 2002; Olson et al., 2011) . The UGTs primarily consist of two large subfamilies, the UGT1As and the UGT2Bs. The UGT1A family, located on chromosome 2q37, codes for nine functional protein isoforms sharing alternative 1st exons spliced to common exons 2-5. The UGT2B family members, located on chromosome 4q13, are expressed as individual genes encoded by six exons each with a unique 39-untranslated region (Mackenzie et al., 2005; Nagar and Remmel, 2006) . The UGTs are generally highly expressed in liver, the primary organ of metabolism, but also extrahepatically in tissues such as lung, the aerodigestive tract, and pancreas, all of which are important targets for tobacco-induced cancers (Beaulieu et al., 1996 Levesque et al., 1997 Levesque et al., , 1999 Strassburg et al., 1997 Strassburg et al., , 1998 Strassburg et al., , 2001 Turgeon et al., 2001; Nakamura et al., 2008b; . Several previous studies have shown differential expression of the UGT1A family of genes, with UGTs 1A1, 1A3, 1A4, 1A5, 1A6 and 1A9 being the primary hepatic isoforms while UGTs 1A7, 1A8, and 1A10 are exclusively expressed extrahepatically (Nagar and Remmel, 2006; Nakamura et al., 2008b; Izukawa et al., 2009; Jones et al., 2012) . UGT2B genes are expressed both hepatically and in several extrahepatic tissues Aueviriyavit et al., 2007; Izukawa et al., 2009; , but few studies have performed a quantitative assessment of the expression of individual UGT2B isoforms in tissues that are targets for tobacco carcinogenesis, including sites within the aerodigestive and respiratory tracts. In addition, extensive interindividual variability of UGT2B expression has been described for individual UGT2B genes within organ sites, and this may contribute to variability in patient response and toxicity (Court et al., 2001; Hoskins et al., 2007; Peterkin et al., 2007) , but few studies have examined UGT2B expression in tissues from multiple individuals. The goals of the present study were to examine the expression of UGT2B genes in tobacco target tissues including tissues of the aerodigestive and respiratory tracts and to examine the interindividual variability of expression of UGT2B genes in these tobacco-related target tissues.
Materials and Methods
Tissue Specimens. The 114 histologically confirmed normal human tissue specimens used to evaluate UGT2B gene expression levels included the same tissues used to examine endogenous control gene expression, and included liver (n = 27), lung (n = 22), larynx (n = 7), tongue (n = 3), floor of mouth (n = 3), tonsil (n = 23), esophagus (n = 13), and pancreas (n = 16). All tissue specimens were from Caucasian individuals and were obtained from the Penn State College of Medicine Tissue Bank, where they had been quick frozen within 2 hours postsurgery. All protocols involving the collection and analysis of tissue specimens were approved by the institutional review board at Penn State University College of Medicine and were in accordance with assurances filed with and approved by the United States Department of Health and Human Services.
RNA Collection and cDNA Synthesis. RNA was extracted from all tissue specimens with the Qiagen RNeasy Mini Kit (Valencia, CA). Samples were subjected to DNase I digestion during extraction to prevent genomic DNA contamination. RNA concentrations were determined using a NanoDrop ND-1000 spectrophotometer, and RNA purity was assessed by absorbance ratios A260/A280 (.1.9) and A260/A230 (.1.8). RNA integrity was determined using an Agilent 2100 Bioanalyzer with Agilent RNA 6000 Nano chips (Santa Clara, CA). All RNA samples used for analysis had RNA integrity numbers (RINs) greater than 5.0. Reverse transcription was performed using the Invitrogen Superscript First Strand cDNA synthesis kit (Carlsbad, CA) with oligo(dT) primers and 1 mg of starting RNA per sample. A negative control without RNA and a negative control without reverse transcriptase enzyme were analyzed in parallel.
Determination of Real-Time Polymerase Chain Reaction Kinetics for MT-ATP6 Gene and UGT2B Target Genes. As described in the Supplemental Materials and Methods to the present study, the real-time polymerase chain reaction (qPCR) kinetics of the MT-ATP6 gene was tested and compared with several (n = 31) putative target genes. MT-ATP6 was shown to exhibit the lowest percent covariance within the majority of tissues (6 out of 10 tissue sites) and the lowest percent covariance between different tissue sites (4.2%) (Supplemental Table 1 ). The range of Ct values for MT-ATP6 was less than 3.0 cycles, suggesting that it was the most stably expressed control gene analyzed (Supplemental Fig. 1 ). For this reason, MT-ATP6 was chosen as the experimentally validated housekeeping gene for the current study. For a more complete discussion of housekeeping gene analysis and selection, please refer to the Supplemental Data file (includes Supplemental Materials and Methods, Results, and Discussion). For developing UGT2B and MT-ATP6 standard curves, 1 mg RNA from pooled human liver was reverse-transcribed as described above and the resulting cDNA was serially diluted. ABI gene expression assays (Life Technologies, Grand Island, NY) were used to amplify MT-ATP6, UGT2B4, UGT2B7, UGT2B10, UGT2B11, UGT2B15, and UGT2B17. The resulting average Ct values were plotted against the cDNA dilution, and the qPCR efficiency values for each of the real-time PCR assays was calculated from the slope of these standard curves using the formula,
, where E x is the amplification efficiency of the given qPCR gene expression assay. These curves were also used to determine the Ct value at which UGT2B gene expression assays become unreliable. For most, this occurred near a Ct value of 35; samples with Ct values greater than 35 were deemed below the limit of quantification (BLQ), even if there was a trace amount of transcript present.
Determination of UGT2B Expression Levels in Human Tissue Specimens via Real-Time Polymerase Chain Reaction. Amplification by qPCR was carried out using a 25-ng RNA equivalent of cDNA. Expression levels were normalized to the expression of the MT-ATP6 gene. Quadruplicate qPCR reactions were performed for each cDNA sample using a 10-ml final reaction volume containing 5 ml of 2Â TaqMan Universal PCR Master Mix, 4.5 ml of diluted cDNA, and 0.5 ml of gene expression assay. Reactions were performed in 384-well plates using the ABI Prism 7900 HT Sequence Detection System (Life Technologies) under the following conditions: 1 cycle at 50°C for 2 minutes, 1 cycle at 95°C for 10 minutes, and 40 cycles of 95°C for 15 seconds and 60°C for 1 minute.
The relative quantitation (RQ) of expression was calculated using the DDCt method. Briefly, DCt was calculated as the Ct value of the target gene minus the Ct of the control gene (MT-ATP6). The DDCt was then calculated as the DCt of the sample minus the DCt of a calibrator sample, in this case the geometric mean of the highest expressed UGT2B isoform in a given tissue. The RQ was determined with the equation
Data Analysis. For qPCR data, statistical analyses were performed using GraphPad Prism version 5.00. When calculating the mean RQ values, only samples that displayed detectable levels of expression were included in the analysis. Spearman's rank method was used for correlative analysis of expressed UGT2B isoforms in all of the tissues except for tongue and mouth (only three specimens from each site precluded them from being analyzed in this manner).
Results
Relative Expression of UGT2B Genes in Human Tissues. Standard curves were used to calculate real-time PCR efficiency values for the UGT2B genes and MT-ATP6 (Fig. 1) . The slopes of the various Ct versus log 2[cDNA] curves were different for each gene, and the calculated efficiency values ranged from 85.7% to 98.6%. The relative efficiencies were used to correct the RQ values using the formula described under Materials and Methods. As the standard curves for each gene became unreliable beyond 35 cycles, 35 cycles was determined to be the quantitation limit of the realtime PCR assays. In subsequent experiments, any gene that amplified with a mean Ct value . 35 cycles was determined to be BLQ.
The mean relative expression of UGT2B genes in different tissues is shown in Table 1 . All UGT2B isoforms were detected in all human liver tissue specimens examined, as previously reported by other groups (Nakamura et al., 2008a; Izukawa et al., 2009; . Only UGT2B17 exhibited no expression in four of the liver specimens examined, likely because those specimens were from subjects exhibiting the homozygous genotype for the prevalent (30% in Caucasians) UGT2B17 wholegene deletion allele (Wilson et al., 2004; Lazarus et al., 2005; Gallagher et al., 2007) . The relative levels of hepatic expression were highest for UGT2B4, followed by UGT2B7 . UGT2B10 . UGT2B17 . UGT2B15 . UGT2B11 (Table 1) . The mean hepatic expression of UGT2B4 was 57% of the total UGT2B expression in human liver, followed by UGT2B7 (32%), UGT2B10 (7.6%), UGT2B17 (2.8%), UGT2B15 (0.9%), and UGT2B11 (0.5%). Interindividual differences in hepatic expression ranged by at least 98-fold for all UGT2B genes, with UGT2B17 exhibiting the greatest interindividual differences (4689-fold; not including the four specimens with no expression), followed by UGT2B7 (3039-fold), UGT2B10 (549-fold), UGT2B4 (148-fold), UGT2B15 (102-fold), and UGT2B11 (98-fold) (Fig. 2) . While UGT2B28 amplified in several liver samples, this occurred at Ct values outside the range of the standard curve (i.e., .35 cycles); the expression of UGT2B28 was BLQ for all of the other specimens examined in this study (results not shown).
In human lung tissue, UGT2B11 was found to be expressed the highest of all UGT2B family members, followed by UGT2B17 . UGT2B4 . UGT2B15 . UGT2B10 . UGT2B7 (Table 1 ). In the 22 human lung tissues analyzed, all six of the UGT2B genes were detected in at least half of the individual specimens. There were significant interindividual differences in expression for UGT2B genes in lung, ranging from 379-fold for UGT2B11 to 27-fold for UGT2B4 ( Fig. 2 ; not including those specimens in which a given UGT2B gene exhibited no expression). UGT2B11 was the only UGT2B gene that was expressed at higher levels (by 2.5-fold) in lung versus liver, with UGT2B17 exhibiting expression levels that were 3.4-fold lower than that observed in human liver.
UGT2B gene expression was detected in individual larynx specimens. The highest expression was seen for UGT2B17, followed by UGT2B11 . UGT2B4 . UGT2B10 . UGT2B15 (Table 1) . UGT2B7
was not detected in any of the individual larynx samples examined. Interindividual differences in expression for UGT2B genes in larynx were less than that observed in lung, ranging from 22-fold for UGT2B4 to 4-fold for UGT2B17 (Fig. 2) . UGTs 2B11 and 2B17 were the only UGT2B genes that were expressed at comparable dmd.aspetjournals.org levels in larynx versus liver (1.1-and 3-fold lower, respectively, in larynx).
In the 13 human esophagus specimens analyzed in this study, several of the UGT2B genes were expressed at very low levels, with UGT2B15 the highest expressed followed by UGT2B17 . UGT2B11 . UGT2B10 . UGT2B4 . UGT2B7 (Table 1) . Compared with human liver tissue, UGT2B genes ranged from 1198-fold lower for UGT2B4 to 21-and 5.4-fold lower for UGTs 2B17 and 2B15, respectively, as compared with that observed in human liver (Fig. 2) ; UGT2B7 was only detected in three of the 13 specimens and was not included in the range estimate. While expression was low for several genes, there was still significant interindividual differences in expression for UGT2B genes, ranging from 63-fold for UGT2B15 to 13-fold for UGT2B7 (Fig. 2) .
With the exception of UGT2B7, UGT2B genes were found to be well-expressed in the majority of human tonsil specimens analyzed. The expression was highest for UGT2B17, followed by UGT2B11 . UGT2B4 . UGT2B10 . UGT2B15 (Table 1) . Compared with their expression in human liver tissue, two UGT2B genes (UGT2B11 and UGT2B17) were expressed at higher levels (6.3-and 2.0-fold higher, respectively), with UGT2B10 and UGT2B15 exhibiting expression levels that were only 3.1-and 1.1-fold lower, respectively (Fig. 3) . Relative to its expression in liver, UGT2B4 expression was relatively low in tonsil (5.5-fold lower). There were significant levels of interindividual difference in UGT2B expression in human tonsil for several UGT2B genes ranging from 2162-fold for UGT2B10 to 577-fold for UGT2B15 (Fig. 2) .
The three floor-of-mouth tissue specimens examined in the present study showed expression of all UGT2B isoforms except UGT2B7. The highest expression observed was for UGT2B17, followed by UGT2B11 . UGT2B4 . UGT2B10 . UGT2B15 (Table 1) . Compared with human liver tissue, UGT2B4 was 288-fold lower, UGT2B10 was 40-fold lower, UGT2B15 was 27-fold lower, UGT2B17 was 7-fold lower, and UGT2B11 was 1.9-fold lower (Fig. 3 ). There were relatively low levels of interindividual difference in expression for the three samples, ranging from 10-fold for UGT2B10 to 2.9-fold for UGT2B17 (Fig. 2) .
In human tongue tissue, detectable levels of expression were observed with UGT2B4 . UGT2B10 . UGT2B11 . UGT2B17 (Table 1) , with their expression ranging from 322-fold lower for UGT2B4 to 4.5-fold lower for UGT2B11 as compared with that observed for human liver (Fig. 3) . Similar to that observed for other upper aerodigestive tract tissues (larynx, tonsil, floor of mouth), no expression of UGT2B7 was detected in any of the tongue tissues analyzed. The interindividual difference in expression ranged from 38-fold for UGT2B4 to 5.3-fold for UGT2B17 (Fig. 2) .
The UGT2B genes were detected in the 16 pancreas specimens, with UGT2B7 . UGT2B17 . UGT2B15 . UGT2B4 . UGT2B11 . UGT2B10 (Table 1) . While significant interindividual differences in expression were observed for UGT2B15 (1043-fold), UGT2B17 (252-fold), and UGT2B7 (181-fold), stable expression levels (1.7-fold differences) were observed for UGT2B10 between pancreas samples (Fig. 2) . UGTs 2B11 (2.0-fold higher) and 2B17 (2.7-fold lower) exhibited expression levels that were comparable to that observed in human liver tissue (Fig. 3) . 
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Correlation between Human UGT2B Gene Expression Levels in Human Tissues. Correlative analysis of UGT2B expression in eight of the tissue sites (for whom at least 4 individual specimens were analyzed) is shown in Table 2 . In liver, there was a significant correlation between the expression of UGTs 2B4, 2B7, 2B10, and 2B15 (all P , 0.01). Hepatic UGT2B11 and UGT2B17 expression levels were not significantly correlated with any of the other UGT2B genes. In lung, the expression of all UGT2B genes except UGT2B4 were significantly (P , 0.01) correlated with each other. In the larynx and tonsil, all of the expressed UGT2B genes were significantly (P , 0.05) correlated with each other with the exception of UGT2B7, which was not expressed at detectable levels in any of the samples. In esophagus, UGTs 2B4, 2B10, 2B11, and 2B17 were significantly (P , 0.01) correlated with each other, but not with 2B15. Unlike that observed for other tissues examined in this study, none of the expressed isoforms were significantly correlated with each other in pancreas, though there was a strong inverse correlation between UGT2B7 and UGT2B10 expression (P , 0.01).
Discussion
In the present study, UGT2B genes were shown to be expressed in tobacco-related tissues. UGT2B17 was shown to be well-expressed relative to other UGT2B genes in most of the tissues examined including larynx, tonsil, esophagus, floor of mouth, pancreas, and lung, all of whom are noted targets for tobacco-induced carcinogenesis (Viswanath et al., 2010) . With the exception of human tongue, UGT2B17 was expressed at the highest or second-highest level of any of the UGT2B genes. UGT2B17 exhibits the highest activity of all UGTs in forming the O-glucuronide of NNAL (Lazarus et al., 2005) , and the UGT2B17 gene deletion is associated with lung adenocarcinoma risk (Gallagher et al., 2007) , a pattern consistent with the high levels of UGT2B17 expression observed in lung in the present study and with NNAL's induction of lung adenocarcinoma in rodent models (Rivenson et al., 1988; Hecht, 1998) . While no studies have examined the role of the UGT2B17 deletion in cancer susceptibility within the aerodigestive tract, relatively high levels of UGT2B17 expression in larynx, tonsil, esophagus, and floor of mouth suggests that the UGT2B17 deletion may play a similarly important etiologic role in the induction of cancers within these tissues.
Previous studies showed that UGT2B7 was found to be active against multiple tobacco carcinogens including NNAL (Ren et al., 2000; Wiener et al., 2004a) and polycyclic aromatic hydrocarbons like B(a)P and DB(a,l)P (Fang et al., 2002; Olson et al., 2011) . In the present study, UGT2B7 was shown to exhibit low or undetectable levels of expression in most tissues examined except for pancreas, where it exhibited highest expression. A UGT2B7 codon 268 singlenucleotide polymorphism resulting in a His . Tyr amino acid change was associated with functional differences in UGT2B7 activity against NNAL (Wiener et al., 2004b) and other substrates (Blevins-Primeau et al., 2009) . Studies are required to examine the role of this and other functional UGT2B7 variants in pancreatic cancer susceptibility. Fig. 3 . Relative expression levels of individual UGT2B genes across different tissues. UGT2B mRNA expression levels were assessed in 113 normal tissue specimens. The log of the relative expression levels for the UGT2B genes is shown. The relative abundance was calculated via the 2 -DDCt method with the geometric mean of the highest expressing tissue set as the calibrator.
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at ASPET Journals on April 7, 2017 dmd.aspetjournals.org UGT2B10 was shown to be the primary enzyme responsible for the formation of NNAL-N-gluc (Chen et al., 2008b ). Relative to other UGT2B genes, UGT2B10 mRNA was expressed at the second-highest level of all UGT2B genes in tongue tissue and could play an important role in tobacco carcinogen detoxification at this site. In addition, like several UGT2B genes, UGT2B10 was expressed in tonsil at levels comparable to that observed in human liver, a pattern suggesting that UGT2B genes, including UGT2B10, play an important role in the glucuronidation of substrates within this tissue. A knockout missense single-nucleotide polymorphism at codon 67 resulting in an aspartic acid to tyrosine amino acid change has been previously characterized for UGT2B10 (Chen et al., 2008a , and this variant could play an important role in tobacco-related cancer risk in these tissues.
Hepatic expression of UGT2B family members has been described (Izukawa et al., 2009; . The highest expressions observed in liver were for UGT2B4 and UGT2B7 followed by UGT2B10, which was largely consistent with these previous studies. UGT2B15 expression in the present study was found to be in concordance with the findings in the Court et al. study, but much lower than the UGT2B15 expression in the Ohno and Nakajin study. In the latter study pooled RNA from three specimens was used for analysis. Given the well-reported interindividual variability for UGT genes, a single outlier specimen with high UGT2B15 expression could have skewed the observed results. UGT2B4 is known as a steroid-and bile acid-glucuronidating UGT, so it is needed in high abundance in the liver (Fournel-Gigleux et al., 1989; Pillot et al., 1993; Levesque et al., 1999) . In contrast, UGTs 2B15 and 2B11 were the lowest expressed UGT2B genes in human liver. UGT2B15 is known primarily for its activity against C 19 steroids (Beaulieu et al., 1996; Levesque et al., 1997) , a characteristic shared by the hepatically abundant UGT2B17, while UGT2B11 exhibits limited substrate specificity against metabolites of arachidonic and linoleic acids (Turgeon et al., 2003) . UGT2B28 expression was below the limit of quantification in the tissue specimens examined in this study, including several liver specimens. While low levels of hepatic UGT2B28 expression were observed in a previous study , the amplification observed for liver specimens in the present study occurred at Ct values outside the range of the standard curve (.35 cycles). The data from the present study are also consistent with previous studies that observed minimal UGT2B28 expression in other human tissues with the notable exceptions being breast and adipose tissue, neither of which was included in the present study.
Interindividual differences in UGT2B expression were large in the tissues examined in this study, making comparisons between individuals difficult. The wide range of expression differences agrees well with previous publications that have assessed this phenomenon (Aueviriyavit et al., 2007; Izukawa et al., 2009 ). The high interindividual differences in expression may be due to multiple genetic, epigenetic, and epidemiologic factors. Tobacco smoke is itself known to contain a number of agents that can induce UGT activity, and thus an individual's smoking habits are likely to influence UGT gene expression levels and enzymatic activity (Villard et al., 1998; Elovaara et al., 2007) . However, as only basic demographic information was available for the subjects from whom these specimens were obtained and the smoking habits of the individuals were unknown, deductions regarding the potential influence of tobacco smoke induction of UGT genes could not be performed. In addition, the high variability may in part be due to the fact that most tissues contain diverse mixtures of cell types; the fact that laser-capture microdissection was not performed, particularly for heterogeneous tissues like lung and pancreas, is a limitation of the present study.
In the liver, the high correlation between the expression of UGT2B4, UGT2B7, UGT2B10, and UGT2B15, but not UGT2B17, is in agreement with previous studies (Izukawa et al., 2009) . This is likely due to a common mechanism of hepatic transcriptional regulation. One potential transcription factor that may explain the correlation between these isoforms is hepatocyte nuclear factor (HNF) 1a, which has been shown to regulate several UGT2B genes (Bernard et al., 1999; Ishii et al., 2000; Gregory, 2004; Barbier et al., 2005; Gardner-Stephen and Mackenzie, 2007) . In addition to liver-enriched transcription factors that regulate basal expression, hepatic UGT expression could potentially be modulated via a number of receptors (Zhou et al., 2005) . For example, UGT2B4 was shown to be regulated by peroxisome proliferator-activated receptor as a mechanism for regulating cholesterol and bile acid metabolism , while UGT2B7 can be induced by the antioxidant-responsive nrf2 pathway (Nakamura et al., 2008a) .
In lung tissue, the correlation of UGT2B17 with other UGT2B genes suggests a coordinated mechanism of regulation in this tissue, and that transcriptional regulation is occurring by different mechanisms in lung versus liver. In the larynx, esophagus, and tonsil, all of the expressed isoforms are well-correlated with each other, suggesting a common regulatory mechanism in these tissues. The lack of correlation of different UGT2B genes in the pancreas suggests a different mechanism of UGT2B regulation in pancreas compared with other tissues examined. Future studies are needed to determine whether individuals with uniformly high or low UGT2B mRNAs display similar correlations at the protein levels. UGT quantitation at the protein level has been problematic due to the high degree of UGT homology, but a recent study demonstrated that the various UGT protein isoforms can be quantified using nano-ultra-high-performance liquid chromatography-tandem mass spectrometry with selected reaction monitoring (Fallon et al., 2013) . However, correlative analyses between the various UGT protein isoforms were not performed in that study.
While previous studies examining UGT mRNA expression have used commonly used housekeeping control genes like 18S rRNA or GAPDH , the MT-ATP6 gene was used as the control gene in the present study. Data from the present study indicated that MT-ATP6 exhibited the least variability of all potential control genes tested when comparing different individuals and tissue sites. These data suggest that MT-ATP6 may be an excellent candidate as a normalization gene for assessing gene expression profiles across multiple tissues from many individuals. The concordance observed in the hepatic UGT2B expression patterns between this and previous quantitative studies, in which either 18S rRNA or GAPDH were assessed, suggests that additional genes other than MT-ATP6 could be used as effective housekeeping genes in liver. A comparison of control gene effectiveness for other tissue sites could not be performed between this and the study by , since UGT2B expression was analyzed for only single lung and pancreas specimens in that study. In the study by , only UGT2B17 was observed in lung, and only UGTs 2B4 and 2B15 were expressed in pancreas, suggesting significant differences in sensitivity between this and the present study, making direct comparisons difficult. No previous studies have examined UGT2B expression in individual sites within the aerodigestive tract.
In summary, specific UGT2B genes important in tobacco carcinogen metabolism were shown to be expressed in various target sites for tobacco-related cancers, with UGTs 2B7, 2B10, and 2B17 wellexpressed in at least several of the tissues examined in this study. These studies also demonstrate a high degree of correlation between UGT2B genes in both hepatic and extrahepatic tissues, suggesting that there are distinct mechanisms of coordinated regulation in extrahepatic tissues, which may have important therapeutic implications. 
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Materials and Methods
Tissue Specimens: The 42 histologically-confirmed normal human tissue specimens utilized to evaluate endogenous control gene expression were from eight sites (six each from the liver, lung, larynx, tonsil, esophagus, and pancreas; and three each from the tongue and floor of mouth).
Determination of expression stability of 31 putative control genes. Applied Biosystems (Carlsbad, CA) endogenous control plates were used for determining the control genes with the greatest expression stability in human tissue specimens. These plates included real-time PCR primers and probes for 32 literature-established control genes including the following: 18S rRNA, ABL1, ACTB, B2M, CASC3, CDKN1A, CDKN1B, EIF2B1, ELF1, BADD45A, GAPDH, GUSB, HMBS, HPRT1, IPO8, MRPL19, MT-ATP6, PES1, PGK1, POLR2A, POP4, PP1A, PSMC4, PUM1, RPL30, RPL37A, RPLP0, RPS17, TBP, TFRC, UBC, and YWHAZ; 18S rRNA was excluded because it is not a polyadenylated RNA species and oligo (dT) was used for the RT reaction. Quadruplicate real-time PCR reactions were performed for each cDNA sample using a 10 μL final reaction volume containing 5 μL 2X Taqman Universal PCR Master Mix, 4.5 μL of diluted cDNA, and 0.5 μL of gene expression assay. A 22.5 ng RNA equivalent of cDNA was used in all Jones, NR and Lazarus, P UGT2B gene expression analysis in multiple tobacco carcinogen-targeted tissues Drug Metabolism and Disposition 2 reactions. Reactions were performed in 384-well plates using the ABI 7900 HT Sequence Detection System under the following conditions: 1 cycle at 50°C for 2 min, 1 cycle at 95°C for 10 min, and 40 cycles of 95°C for 15 sec and 60°C for 1 min.
After calculating the mean Ct value and standard deviation for each of the 31 control genes in the different tissue specimens, the expression stability of each gene was examined by determining the percent covariance of each gene. Percent covariance was calculated using the formula, 100*(stdev/mean). The expression stability between different tissue sites was then determined by ranking the percent covariance across all tissue samples for each gene.
Results
Expression stability of control genes in different tissues. As previous quantitative UGT gene expression studies have utilized 'housekeeping' genes like GAPDH or 18S ribosomal RNA (rRNA) , a secondary goal was to identify a stably-expressed control gene for expression analysis across multiple specimens from eight different tissue types. Of the 31 putative control genes assayed, MT-ATP6 was determined to be among the most stably-expressed control genes both within and between different tissues, and was used as the control gene to determine the levels of expression of UGT2B genes in the present study. of its values separated by less than 2.0 cycles. This is less than a 4-fold difference in expression of MT-ATP6 for the middle 50 percent of the tissue samples.
Discussion
To better assess the expression of potential control genes across multiple specimens from various organ sites, 31 putative control genes were assayed for expression across multiple specimens and organ sites, with mitochondrial ATP-synthase subunit 6 (MT-ATP6) exhibiting the lowest percent covariance within the majority of tissues (6 out 10 tissue sites) and the lowest percent covariance between different tissue sites (4.2%).
There are many variables that affect the efficiency and reproducibility of RT-qPCR expression analysis. Total RNA has been used for normalization, with genes such as 18S rRNA frequently used as internal controls for RNA loading. However, rRNA molecules are not polyadenylated, prohibiting the use of oligodT as an RT primer. This necessitates the use of random hexamers, but because of the relatively high abundance of rRNA species it can lead to different efficiencies of RT priming (Vandesompele et al., 2002) . Therefore, the use of 18S rRNA as a normalization gene may be suboptimal because the kinetics of the RT-qPCR occurs with different efficiency during both the reverse transcription and qPCR steps. In contrast, data from the present study demonstrates that the quantification of the MT-ATP6 gene displays similar kinetics compared to various UGT target genes during both reverse transcription and qPCR. In addition, mitochondrial genes such as MT-ATP6 are polyadenylated, making it Two important caveats exist in the use of a mitochondrial gene like MT-ATP6 for normalization. First, mitochondrial genes are transcribed by different polymerases than nuclear mRNA species and may be regulated differently (Solanas et al., 2001 ). For example, two studies have shown that mitochondrial RNAs are reduced in human cancers (Dmitrenko et al., 2005; Abril et al., 2008) , suggesting that MT-ATP6 may be suboptimal in human cancer studies. Secondly, cellular mRNA content may be different in different cell types than mitochondrial RNA fractions (Solanas et al., 2001 ). The disparity in mitochondrial RNA fraction (5%) may not be nearly as large as with rRNA (90-95%) and mRNA (3-5%), but differences in the relative abundance may affect mRNA quantitation.
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